Successful rescue of brain bioenergetics and reduction of Aβ in these individuals could potentially prevent downstream manifestation of other AD hallmarks such as tau, neurodegeneration, and cognitive impairment. The gene discussed is MAPT; the disease is Cognitive impairment.